Resistance to second-line drugs in multidrug-resistant tuberculosis – Authors' reply
Resistance to second-line drugs in multidrug-resistant tuberculosis – Authors' reply
About this item
Full title
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
To do this, we must continue drug development efforts, build capacity of frontline providers for improved diagnosis, develop international standards for phenotypic as well as genetic approaches to drug susceptibility testing for both existing and new drugs, develop optimised treatment procedures, and ensure treatment adherence.
Alternative Titles
Full title
Resistance to second-line drugs in multidrug-resistant tuberculosis – Authors' reply
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1312839762
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1312839762
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(13)60343-8
